Vol. 30 No. Suppl 1 (2013)

Sarcoidosis vasculitis and diffuse lung diseases

Published: 01-09-2013

The 2nd AIR meeting – Working together to translate idiopathic pulmonary fibrosis research into practice

C. Saltini

5
- PDF

Epidemiology of idiopathic pulmonary fibrosis in Europe – an update

I. Annesi-Maesano, H. Nunes, B. Duchemann, et al.

6-12
- PDF
Classification, natural history and staging of idiopathic pulmonary fibrosis

V. Poletti, J. Egan

13-20
- PDF

Inflammation and dysregulated fibroblast proliferation – new mechanisms?

M. Kolb

21-26
- PDF
Molecular biomarkers in idiopathic pulmonary fibrosis and disease severity

B. Crestani

27-32
- PDF

Management of idiopathic pulmonary fibrosis and pulmonary hypertension

K. Schulze

33-36
- PDF
Gastro-oesophageal reflux and idiopathic pulmonary fibrosis

C. Vancheri

37-39
- PDF
Pirfenidone treatment in a patient with IPF and possible initial hypersensitivity pulmonitis

F. Cinetto, C. Agostini

40-43
- PDF
Treatment switching in idiopathic pulmonary fibrosis: from triple therapy to enrollment into a clinical investigational drug trial

C. Valenzuela, J. Ancochea

44-47
- PDF
Management of a patient with familial idiopathic pulmonary fibrosis

S. Böing, S. George, L. Hagmeyer

48-51
- PDF
Long-term management of IPF with pirfenidone – a clinical case study with 5 years follow-up

L. Richeldi, G. Sgalla, S. Cerri

52-62
- PDF

The 2nd AIR meeting - the current context of European IPF research and management

C. Saltini

63-64
- PDF